Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salesse, S.
Right arrow Articles by Verfaillie, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salesse, S.
Right arrow Articles by Verfaillie, C. M.
Vol. 2, 173-182, February 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

BCR/ABL-mediated Increased Expression of Multiple Known and Novel Genes That May Contribute to the Pathogenesis of Chronic Myelogenous Leukemia1

Stephanie Salesse and Catherine M. Verfaillie2

Stem Cell Institute, Cancer Center and Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455

2 To whom requests for reprints should be addressed, at University of Minnesota Stem Cell Institute, MMC 716, 420 Delaware Street SE, Minneapolis, MN 55455. Phone: (612) 625-0602; Fax: (612) 624-2436; E-mail: verfa001{at}tc.umn.edu

The BCR/ABL chimeric protein plays a central role in the pathogenesis of chronic myelogenous leukemia (CML). Intensive research has elucidated many signal transduction pathways activated by BCR/ABL. However, few studies addressed BCR/ABL-dependent alterations in gene expression that may contribute to the pathobiology of CML. To additionally define such downstream genes, we performed a subtractive hybridization between cord blood (CB) CD34+ cells transduced with an MSCV-retrovirus vector containing either enhanced green fluorescent protein (eGFP) alone or p210BCR/ABL-internal ribosome entry site-eGFP. Thirty-four subtracted clones expressed in p210-eGFP but not eGFP-transduced CD34+ cells have been confirmed by Northern blot and sequenced. Fifty-nine percent represent novel proteins, and 41% are homologous to known genes. Quantitative real-time PCR analysis confirmed that 14 of 14 genes tested were also overexpressed in additional populations of p210BCR/ABL-transduced CB CD34+ cells, as well as in CD34+ cells from primary newly diagnosed CML patients versus GFP-transduced CB or samples from normal donors. Western blot analysis showed that the known sequences were also overexpressed at the protein level. Treatment of BCR/ABL+ cells with the Abl-specific tyrosine kinase inhibitor STI571 decreased expression at the mRNA as well as protein level of some but not all of the gene products. This suggests that increased gene expression is in some cases tyrosine kinase-independent. Some of the overexpressed genes are implicated in cellular processes known to be disturbed in CML, including the mitogen-activated protein kinase or the ubiquitin pathway, whereas overexpression of other genes, including RAN and NUP98, may implicate new cellular pathways involved in CML. Additional characterization of downstream genes activated by BCR/ABL may lead to important new insights in the molecular mechanisms underlying CML and identify potentially novel therapeutic targets for CML.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Tringali, B. Lupo, L. Anastasia, N. Papini, E. Monti, R. Bresciani, G. Tettamanti, and B. Venerando
Expression of Sialidase Neu2 in Leukemic K562 Cells Induces Apoptosis by Impairing Bcr-Abl/Src Kinases Signaling
J. Biol. Chem., May 11, 2007; 282(19): 14364 - 14372.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. D. Unwin, D. W. Sternberg, Y. Lu, A. Pierce, D. G. Gilliland, and A. D. Whetton
Global Effects of BCR/ABL and TEL/PDGFR{beta} Expression on the Proteome and Phosphoproteome: IDENTIFICATION OF THE RHO PATHWAY AS A TARGET OF BCR/ABL
J. Biol. Chem., February 25, 2005; 280(8): 6316 - 6326.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Ray, Y. Lu, S. H. Kaufmann, W. C. Gustafson, J. E. Karp, I. Boldogh, A. P. Fields, and A. R. Brasier
Genomic Mechanisms of p210BCR-ABL Signaling: INDUCTION OF HEAT SHOCK PROTEIN 70 THROUGH THE GATA RESPONSE ELEMENT CONFERS RESISTANCE TO PACLITAXEL-INDUCED APOPTOSIS
J. Biol. Chem., August 20, 2004; 279(34): 35604 - 35615.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.